COVID-19 in patients receiving treatment at an outpatient chemotherapy unit
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyae129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Shiori Kinoshita und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Nagoya City University, Nagoya, Japan. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
During the COVID-19 pandemic period, many patients who required outpatient chemotherapy developed COVID-19, requiring chemotherapy interruption. However, there are no clear guidelines regarding the safe timing for restarting chemotherapy. We conducted a retrospective study to assess when such patients can safely recommence chemotherapy. Of the 40 patients included in this study, 34 restarted anticancer drug therapy after COVID-19 infection. Six patients, four with multiple myeloma, and one each with follicular lymphoma and glioma, remained SARS-CoV-2 antigen positive >20 days after COVID-19 onset. Multiple myeloma patients recorded significantly higher frequencies of SARS-CoV-2 antigen positivity >20 days after COVID-19 onset compared with solid tumor patients, with no significant differences in the frequency of SARS-CoV-2 positivity during 5–20 days from COVID-19 onset between them. According to our data, most solid tumor patients achieved SARS-CoV-2 antigen negativity after 20 days from COVID-19 onset. On the other hand, multiple myeloma patients might need serial antigen tests before restarting anticancer therapy in the outpatient chemotherapy setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Nagoya City University, Nagoya, Japan.
- Department of Hematology and Oncology, Nagoya City University, Nagoya, Japan.
- Department of Pharmacy, Nagoya City University, Nagoya, Japan.
- Department of Nursing, Nagoya City University, Nagoya, Japan.
ORCID-Profile: Shiori Kinoshita
Zitieren
APA
Kinoshita, S., Takemoto, M., Asaoka, M., Haraguchi, Y., Adachi, T., Iida, S., & Komatsu, H. (2025). COVID-19 in patients receiving treatment at an outpatient chemotherapy unit. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae129
Vancouver
Kinoshita S, Takemoto M, Asaoka M, Haraguchi Y, Adachi T, Iida S, et al. COVID-19 in patients receiving treatment at an outpatient chemotherapy unit. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae129
BibTeX
@article{Kinoshita2025,
author = {Kinoshita, Shiori and Takemoto, Masashi and Asaoka, Minami and Haraguchi, Yoko and Adachi, Tamami and Iida, Shinsuke and Komatsu, Hirokazu},
title = {COVID-19 in patients receiving treatment at an outpatient chemotherapy unit},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyae129}
}
EUVIMED